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1. INTRODUCTION {#jcmm14137-sec-0001}
===============

Marfan syndrome (MFS) is an inherited autosomal connective tissue disorder caused by mutations in an extracellular matrix protein, fibrillin‐1 (*FBN1*), with manifestations in the cardiovascular system, eye, skeleton, lung, skin and dura.[1](#jcmm14137-bib-0001){ref-type="ref"} The major complication is aortic dissection, which generally occurs in the presence of aortic root dilatation. In MFS, the extracellular matrix undergoes remodelling with increase in aortic stiffness and progressive weakening of the aortic wall leading to aortic dissection.

Extensive research has been conducted using mouse models with mutant fibrillin‐1 (*Fbn1*) that develop MFS‐like aortopathy despite normal aortic elastogenesis.[2](#jcmm14137-bib-0002){ref-type="ref"}, [3](#jcmm14137-bib-0003){ref-type="ref"}, [4](#jcmm14137-bib-0004){ref-type="ref"} Two mice models, Fbn1^C1039G/+^ and mgR/mgR with different degrees of MFS pathologies, have frequently been used in MFS studies.[3](#jcmm14137-bib-0003){ref-type="ref"}, [4](#jcmm14137-bib-0004){ref-type="ref"}, [5](#jcmm14137-bib-0005){ref-type="ref"}, [6](#jcmm14137-bib-0006){ref-type="ref"} In the Fbn1^C1039G/+^ model, it has been observed that 90% of animals develop the variable severe phenotype and \~5% of animals die by 8 months of age as a result of aortic aneurysms.[5](#jcmm14137-bib-0005){ref-type="ref"} On contrary, the mgR/mgR (hypomorphic) model produces \~20% normal fibrillin1 that develops a severe form of MFS with an earlier onset and an average survival of 2.5 months.[2](#jcmm14137-bib-0002){ref-type="ref"}, [7](#jcmm14137-bib-0007){ref-type="ref"}

Previous research has suggested that the pathophysiology of MFS can be explained by ongoing abnormalities in TGF‐beta signalling that lead to progressive destabilization of the aortic wall and it has been suggested that fibrillin‐1 interacts with latent TGF‐beta binding proteins (LTBPs) to restrict TGF‐beta activation.[8](#jcmm14137-bib-0008){ref-type="ref"}, [9](#jcmm14137-bib-0009){ref-type="ref"} Hence, the deficiency of fibrillin‐1 in MFS promotes the release and activation of TGF‐beta. Several studies have shown that there is an increased abundance of TGF‐beta in MFS.[8](#jcmm14137-bib-0008){ref-type="ref"}, [10](#jcmm14137-bib-0010){ref-type="ref"} In addition, non‐canonical TGF‐beta signalling pathway (extracellular signal‐regulated kinase \[ERK\] 1 and 2) has also been shown to promote aortic aneurysms in Marfan mice.[11](#jcmm14137-bib-0011){ref-type="ref"} TGF‐beta neutralizing antibodies (1D11) and Losartan (an angiotensin II type 1 receptor \[AT1\] antagonist) have been shown to decrease TGF‐beta signalling in Marfan mouse models. Furthermore, aortic extracts containing elastin/fibrillin fragments with GxxPG motifs significantly increased macrophage chemotaxis.[12](#jcmm14137-bib-0012){ref-type="ref"}, [13](#jcmm14137-bib-0013){ref-type="ref"} Subsequent treatment of Marfan mice with a neutralizing antibody (BA4 ‐ anti‐elastin, monoclonal antibody) decreased macrophage chemotaxis, inflammation and degeneration of the vessel architecture.[12](#jcmm14137-bib-0012){ref-type="ref"}

Overall, in the last decade, the leading hypothesis has been that TGF‐beta induction is a major driver of Marfan disease progression. This assumption was recently challenged by selectively deleting the TGF‐type‐II receptor in MFS mice (Fbn1^C1039G/+^) suggesting that increased TGF‐beta in MFS may not be the sole cause of MFS aortopathy.[14](#jcmm14137-bib-0014){ref-type="ref"} Consequently, these results suggest that there may be previously unrecognized mechanisms, by which MFS disease progression is regulated and potential etiologies of MFS need further examination.

With an aim to gain insight into the molecular mechanisms and novel transcripts governing the progression of disease in MFS, we performed RNA‐sequencing of aortic tissues from Marfan (mgR/mgR) vs WT mice and identified several new factors associated with Marfan‐induced aortic disease progression.

2. MATERIALS AND METHODS {#jcmm14137-sec-0002}
========================

2.1. Animal experiments and isolation of ascending aortas from mice {#jcmm14137-sec-0003}
-------------------------------------------------------------------

Heterozygous *Fbn1* underexpressing mice (25) were mated to generate homozygous mgR/mgR and WT mice. Genotyping was performed as previously described.[15](#jcmm14137-bib-0015){ref-type="ref"} Mice were maintained under pathogen‐free conditions, and the ethical guidelines for animal work and the animal experiments were approved by the Landesamt für Gesundheit und Soziales in Berlin (LaGeSo Reg. No. 0024/14). Mice were sacrificed; the ascending aortas and arch of the mgR/mgR homozygous and WT animals were isolated and pooled for subsequent RNA expression analysis.

2.2. Van Giesson staining {#jcmm14137-sec-0004}
-------------------------

Aortic architecture was assessed using elastic van Giesson staining kit from Sigma‐Aldrich, following the manufacturer\'s instructions.

2.3. RNA‐sequencing analysis {#jcmm14137-sec-0005}
----------------------------

Total RNA was extracted from WT and mgR/mgR homozygous animals (9 weeks old animals) using the RNeasy mini kit (Qiagen). Library preparation was done using the TruSeq RNA Library Preparation Kit v2 (Illumina) following the manufacturer\'s instructions. An Illumina HiSeq 2500 sequencing device was used to perform the high throughput sequencing, to generate 65‐75 million reads of 50‐bp paired‐end reads, with a mean insert size of 150 bp. The reads were mapped to Mus musculus genome build (mm9) using TopHat2.[16](#jcmm14137-bib-0016){ref-type="ref"} DESeq2[17](#jcmm14137-bib-0017){ref-type="ref"} was used for differential expression analysis with a false discovery rate of 0.05% (FDR).

2.4. qRT‐PCRs {#jcmm14137-sec-0006}
-------------

Freshly dissected aortic tissues were snap‐frozen in liquid nitrogen. Frozen tissues were pulverized and RNA was isolated using Qiagen RNeasy Mini kit following the manufacturer\'s instructions. For reverse transcription, 1 microgram of RNA was used for conversion into cDNA using the RevertAid H minus cDNA Synthesis Kit (ThermoFisher Scientific). Real‐time PCR was performed on the Applied Biosystems 7900HT real‐time PCR machine as described previously.[18](#jcmm14137-bib-0018){ref-type="ref"} Gapdh was used as endogenous control. Refer to Data [S1](#jcmm14137-sup-0011){ref-type="supplementary-material"} for qPCR primers.

2.5. Western blots {#jcmm14137-sec-0007}
------------------

Aortic samples were homogenized using FastPrep^®^‐24 Classic instrument for 20 seconds. Protein isolation was done using the QIAGEN AllPrep DNA/RNA/Protein Mini Kit, following the manufacturer\'s instructions, in the presence of protease and phosphatase inhibitors. Proteins were quantified using the Pierce BCA kit. Proteins (30 μg) were loaded on 10% SDS‐PAGE gels and transferred onto nitrocellulose membranes. After blocking (3% milk in 0.1% PBS‐T), membranes were incubated with corresponding primary antibodies overnight at 4°C. Immunoreactive proteins were detected using ECL Plus (GE Healthcare, Buckinghamshire, UK). Refer to Data [S1](#jcmm14137-sup-0011){ref-type="supplementary-material"} for antibody details.

2.6. Pathway classification {#jcmm14137-sec-0008}
---------------------------

The gene functional annotation was performed using the DAVID functional annotation tool[19](#jcmm14137-bib-0019){ref-type="ref"} (<https://david.ncifcrf.gov/>) followed by KEGG pathway analysis with an ease score of 0.03 and gene count of 5 genes per pathway.

3. RESULTS {#jcmm14137-sec-0009}
==========

3.1. Differential gene regulation in the aorta of WT vs mgR/mgR mice {#jcmm14137-sec-0010}
--------------------------------------------------------------------

To identify novel factors and to gain insight into the molecular mechanisms underlying MFS, we employed mgR/mgR mice comparing them with their WT littermates. First, we performed Van Giesson staining to assess the elastic architecture of the aortic tissue and we found the elastic fibres to be fragmented in the mgR/mgR mice compared to WT mice (Figure [1](#jcmm14137-fig-0001){ref-type="fig"}A), a phenomenon commonly seen in MFS.[2](#jcmm14137-bib-0002){ref-type="ref"}, [20](#jcmm14137-bib-0020){ref-type="ref"}

![RNA‐sequencing analysis of WT vs mgR/mgR aorta. A, Verhoeff‐van Gieson staining in wild‐type (WT) vs mgR/mgR mouse. Van Gieson staining was performed on aortas isolated from wild‐type and mgR mice. Increased elastin fragmentation and breaks were observed in Marfan mice, compared to wild‐type. B, Differential expression of genes by RNA‐ sequencing analysis in WT vs mgR/mgR aortas (9 wk) animals. Heatmap depicting the Log2 FKPM values of significantly regulated genes (*P* \< 0.05). The red colour indicates the low expression of genes and white indicates the high expression of genes. C, Comparison of our RNA‐sequencing data to published microarray (Schwill, Seppelt et al. 2013). Our comparison identified, 23 genes to be commonly regulated between both and 225 genes to be exclusively regulated in our dataset and 126 genes exclusive to Schwill, Seppelt dataset](JCMM-23-2526-g001){#jcmm14137-fig-0001}

Next, we performed RNA‐sequencing of aortic tissues from homozygous mgR/mgR vs WT mice. Our analysis revealed that 248 genes were differentially regulated between the two groups (Figure [1](#jcmm14137-fig-0001){ref-type="fig"}B, Table [S1](#jcmm14137-sup-0004){ref-type="supplementary-material"}), with 144 genes being up‐regulated and 104 being down‐regulated in WT vs mgR/mgR mice (Table [S1](#jcmm14137-sup-0004){ref-type="supplementary-material"}). Importantly, our analysis revealed 20 transcripts previously unknown to be differentially expressed in the aorta of MFS mice (Table [S2](#jcmm14137-sup-0005){ref-type="supplementary-material"}).

Gene ontology (GO) analysis of the RNA‐sequencing data revealed the enrichment of gene signatures in GO terms, such as adrenergic signalling in cardiomyocytes, dilated and hypertrophic cardiomyopathy (HCM), chemokine signalling, cardiac muscle contraction and calcium signalling pathway, that are relevant to cardiovascular complications and MFS (Table 2, Table [S3](#jcmm14137-sup-0006){ref-type="supplementary-material"}).

We then compared our RNA‐sequencing dataset (9 weeks old aortas, mgR/mgR mice) to a published microarray dataset (6 weeks old aortas, mgR/mgR mice) [15](#jcmm14137-bib-0015){ref-type="ref"} and identified 23 genes to be commonly regulated between the two datasets (Figure [1](#jcmm14137-fig-0001){ref-type="fig"}C, Table [S4](#jcmm14137-sup-0007){ref-type="supplementary-material"}). Interestingly, 225 genes were exclusively regulated in our dataset (Table [S5](#jcmm14137-sup-0008){ref-type="supplementary-material"}), while 126 genes were exclusively regulated in the previously published microarray dataset[15](#jcmm14137-bib-0015){ref-type="ref"} (Table [S6](#jcmm14137-sup-0009){ref-type="supplementary-material"}). Furthermore, we compared our RNA‐sequencing dataset to other aneurysms such as angiotensin II infused ‐ apolipoprotein deficient mouse model of abdominal aortic aneurysms (AAA, 17 weeks old aortas)[21](#jcmm14137-bib-0021){ref-type="ref"} and found 36 genes to be common regulated across both datasets (Table [S7](#jcmm14137-sup-0010){ref-type="supplementary-material"}, Figure [S3](#jcmm14137-sup-0003){ref-type="supplementary-material"}).

3.2. Validation of selected transcripts by qPCR and Western blotting {#jcmm14137-sec-0011}
--------------------------------------------------------------------

We selected and validated the genes randomly (*Lrrc17*,*Gxylt2*,*Mfsd2a*,*Scube* and *Ank2*) and based on their role in aneurysms (*Mmp12*,*Spp1*,*Ctss*) or cardiovascular complications (*Mfap4*,*Igfbp2*) or inflammatory signalling pathways (*Ccls* and *Ccrs*). Our analysis revealed that many genes enriched in chemokine signalling (*Ccl8*,*Ccr5*,*Ccl9*,*Ccl6*,*Ccl7*,*Ccl2* and *Ccl5)* were highly induced in mgR/mgR aortic tissues (Figure [2](#jcmm14137-fig-0002){ref-type="fig"}B,D‐G and Figure [S1](#jcmm14137-sup-0001){ref-type="supplementary-material"}). Another novel candidate gene identified from our sequencing analysis, *Igfbp2*, was found to be highly up‐regulated across independent biological replicates, suggesting that this might be a potential factor for MFS (Figure [2](#jcmm14137-fig-0002){ref-type="fig"}A). Other highly up‐regulated candidates of interest were *Spp1*,*Ctss*,*Cd55*,*Cd53*,*Lmod2*,*Irf7*,*Chrdl1*,*Tmem176b*,*Lgals3*,*MMP12* and *H19* LncRNA in mgR/mgR compared to WT mice (Figure [2](#jcmm14137-fig-0002){ref-type="fig"}C,H,I and Figure [S1](#jcmm14137-sup-0001){ref-type="supplementary-material"}). In addition, we also identified and validated a set of down‐regulated genes by qPCR, such as *Lrrc17*,*Mfap4*,*Ncam1*,*Gxylt2*,*Mfsd2a*,*Scube3*,*Ank2*,*Dsp*,*Myh10*,*Xirp*,*Smoc1*,*Chsy3*,*Adamts17*,*ppp1R36*,*Mylk2*,*Gucy1b3* and *Abcc9* (Figure [3](#jcmm14137-fig-0003){ref-type="fig"} and Figure [S2](#jcmm14137-sup-0002){ref-type="supplementary-material"}). The most significantly up‐ and down‐regulated genes from our RNA‐sequencing data are provided as Table [1](#jcmm14137-tbl-0001){ref-type="table"}. We further assessed the protein levels of key genes identified by RNA‐sequencing. pSMAD2 and pErk1/2 signalling pathways were induced in mgR/mgR compared to WT mice (Figure [4](#jcmm14137-fig-0004){ref-type="fig"}A,B). Furthermore, we demonstrated that Igfbp2 and Ccl8 protein levels are induced (Figure [4](#jcmm14137-fig-0004){ref-type="fig"}C,E) and Mfap4 protein levels are decreased in mgR/mgR compared to WT mice (Figure [4](#jcmm14137-fig-0004){ref-type="fig"}D), which correlates with our aortic RNA‐sequencing data. However, we found Mylk2 protein levels to be increased (Figure [4](#jcmm14137-fig-0004){ref-type="fig"}F), contrary to decreased mRNA levels in mgR/mgR compared to WT mice (Figure [3](#jcmm14137-fig-0003){ref-type="fig"}E).

![Validation of up‐regulated genes from RNA‐sequencing data. A‐E, qPCRs were performed between WT vs mgR/mgR aortas for the up‐regulated genes from RNA‐sequencing data. Fold changes were calculated and Gapdh was used as normalizing control. Data were validated across n = 3 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)](JCMM-23-2526-g002){#jcmm14137-fig-0002}

![Validation of down‐regulated genes from RNA‐sequencing data. A‐G, qPCR was performed between WT vs mgR/mgR aortas for the down‐regulated genes from RNA‐ sequencing data. Fold changes were calculated and Gapdh was used as a normalizing control. Data were validated across n = 3 or n = 2 different biological replicates. Each replicate is derived from three pooled WT vs mgR tissues (11 weeks old)](JCMM-23-2526-g003){#jcmm14137-fig-0003}

###### 

Genes significantly up‐ or down‐regulated in mgR/mgR aortic aneurysms both in RNA‐sequencing and qPCR datasets

  Gene name    RNA‐seq and qPCR (in mgR/mgR)   *P*‐value
  ------------ ------------------------------- -----------
  *Igfbp2*     Up                              5.00E‐05
  *Mfap4*      Down                            5.00E‐05
  *Tmem176b*   Up                              0.00065
  *Irf7*       Up                              5.00E‐05
  *Ccl8*       Up                              5.00E‐05
  *Ccl6*       Up                              0.00025
  *H19*        Up                              2.00E‐04
  *Ccl9*       Up                              0.00015
  *Spp1*       Up                              0.00045
  *Ctss*       Up                              5.00E‐05
  *Myh10*      Down                            0.00035
  *Lrrc17*     Down                            5.00E‐05
  *Scube3*     Down                            5.00E‐05
  *Gxylt2*     Down                            5.00E‐05
  *Ncam1*      Down                            5.00E‐05
  *Mfsd2a*     Down                            0.00015
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![Protein validations of identified genes from RNA‐sequencing data by Western blots. A) pSmad2 and B) pErk1/2 protein levels were induced in mgR/mgR aortic tissues compared to WT (11 weeks old animals). Up‐regulation of C) Igfbp2, E) Ccl8 and F) Mylk2 protein levels and Down‐regulation of D) Mfap4 protein levels in mgR/mgR aortic tissues compared to WT. Protein lysates were harvested as described in methods sections. Gapdh or Hsp60 was used as a loading control](JCMM-23-2526-g004){#jcmm14137-fig-0004}

4. DISCUSSION {#jcmm14137-sec-0012}
=============

In this study, we set out to identify novel differentially expressed genes during MFS in mgR/mgR aortas using RNA‐sequencing. Our analysis revealed many previously unknown genes to be significantly regulated in mgR/mgR mice.

The predominant paradigm of MFS pathophysiology in recent years has focussed on alterations of TGF‐beta signalling. Moreover, high levels of circulating TGF‐beta were observed in Marfan mouse models and patients, suggesting it is an important factor involved in MFS.[22](#jcmm14137-bib-0022){ref-type="ref"}, [23](#jcmm14137-bib-0023){ref-type="ref"} Most of the treatment regimens adopted have been to antagonize TGF‐beta signalling with neutralizing antibodies or Losartan. However, more recent literature demonstrated that the deletion of the TGF‐beta receptor II (Tgfbr2) increases the aortopathy in Marfan animals, thus suggesting a complicated role of TGF‐beta signalling in MFS[7](#jcmm14137-bib-0007){ref-type="ref"}, [14](#jcmm14137-bib-0014){ref-type="ref"} and also the possibility of other potential regulators and mechanisms underlying the MFS phenotype.

To this extent, one of our novel findings is the regulation of Igfbp2, which was significantly induced in mgR/mgR vs WT aortas in our RNA‐ sequencing, qPCR and immunoblotting data. Igfbp2, a secreted protein, belongs to a class of insulin like growth factor binding proteins (Igfbp1‐6), which bind to IGF1, IGF2 and insulin and signal via IGF1R, IGF‐IIR/M6P and insulin receptors, thus transducing the signal to the nucleus, followed by transcriptional activation of specific genes to promote proliferation and differentiation. There have been conflicting reports about the role of Igfbp2 in cancers, as there is evidence supporting it to be both a tumour suppressor and an oncogene in different cancers.[24](#jcmm14137-bib-0024){ref-type="ref"} In glioma cells, Igfbp2 promotes pERK1/2 phosphorylation via integrin β1, thus regulating cell proliferation and invasion.[25](#jcmm14137-bib-0025){ref-type="ref"} It is known that pERK1/2 levels are induced in MFS mice and it has been proposed that abolishing pERK1/2 levels could be a potential therapy towards MFS.[11](#jcmm14137-bib-0011){ref-type="ref"}, [20](#jcmm14137-bib-0020){ref-type="ref"}

In addition, it was shown that ERK1/2 signalling is limited to non‐myocyte compartment of MFS mouse heart and upon pressure overload, it contributes to cardiomyopathy, emphasizing ERK signalling to be a crucial therapeutic target in MFS.[26](#jcmm14137-bib-0026){ref-type="ref"} Here, we speculate that the induced Igfbp2 levels in mgR/mgR mice could be crucial in regulating pERK1/2 levels in MFS and this needs further investigation.

Furthermore, Mfap4 was highly down‐regulated in mgR/mgR mice. Mfap4 is an extracellular glycoprotein that specifically binds tropoelastin, fibrillin‐1 and fibrillin‐2.[27](#jcmm14137-bib-0027){ref-type="ref"} It is expressed in elastic tissues, such as aorta, skin and lung, and is localized to elastic fibres of these tissues.[28](#jcmm14137-bib-0028){ref-type="ref"}, [29](#jcmm14137-bib-0029){ref-type="ref"}, [30](#jcmm14137-bib-0030){ref-type="ref"} In dermal fibroblasts, MFAP4 interacts directly with fibrillin‐1 and plays a crucial role in microfibril development and maintenance of ECM proteins.[31](#jcmm14137-bib-0031){ref-type="ref"} In mgR/mgR hypomorphic animals, Fbn1 levels are low (\~20% normal Fbn1 produced) and this corresponds with low level of expression of Mfap4 in our data (RNA‐sequencing, qPCR and Western), suggesting a possible important mechanistic role of Mfap4‐fibrillin‐1 interaction in MFS. However, MFAP4 protein levels were found to be up‐regulated in Marfan patients,[32](#jcmm14137-bib-0032){ref-type="ref"} suggesting there could be differential regulation of MFAP4 in different disease model systems or between species. Our results on Mfap4 shed light on a potentially crucial regulator in MFS that needs further investigation.

We identified different chemokines to be highly up‐regulated in MFS (Figure [2](#jcmm14137-fig-0002){ref-type="fig"}D‐G). Medial necrosis and presence of inflammatory cells is well known in MFS. T cells (CD8+ and CD4+) have been shown in adventitia of MFS aortas, emphasizing a crucial role of immune cells in both medial and adventitial layers of MFS aorta.[33](#jcmm14137-bib-0033){ref-type="ref"} Previously, studies have reported inflammatory genes to be involved in both mouse and human AAA.[15](#jcmm14137-bib-0015){ref-type="ref"}, [21](#jcmm14137-bib-0021){ref-type="ref"}, [34](#jcmm14137-bib-0034){ref-type="ref"} Among the chemokines identified in our data, Ccl8 was highly up‐regulated at both RNA (in RNA‐ sequencing, qPCRs datasets) and protein levels. Apart from *Ccl8*, we identified *Ccr5*,*Ccl5*,*Ccl2*,*Ccl7* and *Ccl9*, to be highly up‐regulated in mgR/mgR mice. *Ccl8* was also shown to be induced during AAA in mice.[21](#jcmm14137-bib-0021){ref-type="ref"} The role of IL6‐STAT3 signalling in contributing to aneurysm dilation has been shown in mgR/mgR Marfan model.[35](#jcmm14137-bib-0035){ref-type="ref"} In MFS patients, inflammation correlated with aortic disease, emphasizing the crucial role of inflammatory signalling in aortic disease progression.[33](#jcmm14137-bib-0033){ref-type="ref"} It is known that defective fibrillin‐1 in MFS leads to impaired collagen and network organization. This might lead to further collagen damage and the release of degradation products that could possibly activate inflammatory pathways.[33](#jcmm14137-bib-0033){ref-type="ref"} However, in Fbn1^C1039G/+^ Marfan model the anti‐inflammatory therapy did not show beneficial effect on aortic dilatation, suggesting a complex role of inflammation in different MFS model systems.[36](#jcmm14137-bib-0036){ref-type="ref"} Overall, it is unclear, if inflammation is the cause or the consequence of aortic dilation and its role in MFS is not clearly understood. Collectively, our study reveals the importance of several inflammatory genes that can be potential targets for novel anti‐inflammatory therapeutics.

We also found *Spp1*,*Mmp12* and *Ctss* to be significantly up‐regulated in mgR/mgR mice. Spp1 is a multifunctional phosphoprotein, expressed in various cell types and a known biomarker for cardiovascular diseases.[6](#jcmm14137-bib-0006){ref-type="ref"}, [37](#jcmm14137-bib-0037){ref-type="ref"} Elevated Spp1 levels have been observed in circulation in different cancers, autoimmune disease and AAA. Spp1 has been shown to be involved in the regulation of chronic inflammation and recruitment of T cell and macrophages and regulates cytokine production in macrophages and T cells.[38](#jcmm14137-bib-0038){ref-type="ref"} The levels of OPN have been found to be elevated in AAA patients (both in plasma and aortic wall) and it may drive AAA formation.[39](#jcmm14137-bib-0039){ref-type="ref"} In addition, the local application of osteopontin enhanced vascular healing by decreasing the calcification and maintaining the luminal integrity in rabbit thoracic aortas.[40](#jcmm14137-bib-0040){ref-type="ref"} In addition, a single SNP in TgfbrII had altered Spp1 secretion after adjusting for multiple testing.[41](#jcmm14137-bib-0041){ref-type="ref"} However, the mechanistic regulation of Spp1 in Marfan aortic aneurysms is not clear. It is known that the complex pathogenesis of MFS involves an imbalance in expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMP activity.[42](#jcmm14137-bib-0042){ref-type="ref"} More specifically, *Mmp2*,*Mmp9* and *Mmp12* have been shown to be up‐regulated in mgR/mgR mice.[43](#jcmm14137-bib-0043){ref-type="ref"} We identified the same trend in *Mmp12* expression. These results emphasize the importance of *Spp1*,*Ctss* and *Mmp12* in mgR/mgR disease progression.

Apart from coding genes, we also found the *H19* LncRNA to be significantly up‐regulated in mgR/mgR mice. H19 is a conserved and imprinted lncRNA having many biological functions in different diseases. Increased levels of *H19* are associated with increased risk of coronary artery disease in patients.[44](#jcmm14137-bib-0044){ref-type="ref"} In addition, *H19* was induced in heart failure patients.[45](#jcmm14137-bib-0045){ref-type="ref"} *H19* in association with miR‐675 axis was shown to regulate cardiomyocyte apoptosis and diabetic cardiomyopathy.[46](#jcmm14137-bib-0046){ref-type="ref"}, [47](#jcmm14137-bib-0047){ref-type="ref"} The same axis (H19‐miR‐675) is reported to function as a negative regulator of cardiomyocyte hypertrophy in mice.[48](#jcmm14137-bib-0048){ref-type="ref"} However, the role of H19 in context of MFS is unclear and we believe it could be an interesting target to investigate.

Moreover, we identified several genes to be commonly regulated between our RNA‐ sequencing dataset and a previously published microarray datasets,[15](#jcmm14137-bib-0015){ref-type="ref"}, [21](#jcmm14137-bib-0021){ref-type="ref"} suggesting the significance and importance of these genes in MFS. Furthermore, our approach identified several genes, such as *Lrrc17*,*Mfap4*,*Ncam1*,*Gxylt2*,*Mfsd2a*,*Scube3*,*Ank2*,*Dsp*,*Myh10*,*Xirp*,*Smoc1*,*Chsy3*,*Adamts17*,*ppp1R36*,*Mylk2*,*Gucy1b3* and *Abcc9 to be* significantly down‐regulated in mgR/mgR aortas, whose regulation has not been previously related to MFS. However, we found Mylk2 protein levels to be induced in mgR/mgR mice, suggesting possible posttranscriptional regulation of this particular gene.

GO analysis of differentially regulated genes revealed relevant pathways involved in cardiovascular biology and MFS, such as adrenergic signalling in cardiomyocytes, dilated cardiomyopathy, HCM, calcium signalling pathway, chemokine signalling pathway and others (Table [2](#jcmm14137-tbl-0002){ref-type="table"}). The crucial role of adrenergic signalling in cardiac diseases is recognized. It is known that hyperactivity of β‐adrenergic signalling and increase in ROS production contribute to cardiac hypertrophy and heart failure.[49](#jcmm14137-bib-0049){ref-type="ref"}, [50](#jcmm14137-bib-0050){ref-type="ref"} In addition, β‐adrenergic blockade using propranolol decreased the aortic dilatation and complications and improved the clinical manifestations of MFS,[51](#jcmm14137-bib-0051){ref-type="ref"}, [52](#jcmm14137-bib-0052){ref-type="ref"} emphasizing its crucial role in MFS. The other GO enriched pathway from our data was dilated cardiomyopathy that has been shown to be the primary manifestation of MFS, which results from ECM‐induced abnormal mechanosignalling by cardiomyocytes.[53](#jcmm14137-bib-0053){ref-type="ref"} Furthermore, dilated cardiomyopathy in an MFS patient was accompanied by chronic type A aortic dissection and right atrial thrombus.[54](#jcmm14137-bib-0054){ref-type="ref"} We also found calcium signalling pathway to be overrepresented in our dataset. It is known that calcium influx regulates FBN1 expression.[55](#jcmm14137-bib-0055){ref-type="ref"} Moreover, calcium channel blockers, are used as a second line of therapy in 10%‐20% MFS patients who are intolerant to β‐blockers.[56](#jcmm14137-bib-0056){ref-type="ref"} However, calcium channel blockers have detrimental effects in MFS mice and are associated with an increased risk of cardiovascular pathology in human MFS.[57](#jcmm14137-bib-0057){ref-type="ref"} All these data, highlight the importance of our finding on calcium signalling and its implication in MFS management. Apart from the above mentioned pathways, our data also emphasized the importance of chemokine signalling, which is crucial during MFS.[33](#jcmm14137-bib-0033){ref-type="ref"} However, the exact role of chemokine signalling in MFS is still unclear. The other pathways from our GO analysis, such as focal adhesion, HCM and cardiac muscle contraction have also been implicated in MFS.[58](#jcmm14137-bib-0058){ref-type="ref"}, [59](#jcmm14137-bib-0059){ref-type="ref"}, [60](#jcmm14137-bib-0060){ref-type="ref"} Overall, our GO analysis suggests a specific and crucial role of identified genes and pathways that are relevant in mgR/mgR mice.

###### 

KEGG pathway analysis of differentially regulated genes from RNA‐sequencing data

  Term                                      *P*‐value   Genes
  ----------------------------------------- ----------- ---------------------------------------------------------------------------------
  Adrenergic signalling in cardiomyocytes   0.00026     *Tnnt2*,*Actc1*,*Adcy7*,*Pln*,*Scn4b*,*Myh7*,*Myh6*,*Tnni3*,*Scn5a*
  Dilated cardiomyopathy                    0.00042     *Tnnt2*,*Actc1*,*Adcy7*,*Pln*,*Mybpc3*,*Ttn*,*Tnni3*
  Focal adhesion                            0.00072     *Myl7*,*Lamc3*,*Mylk3*,*Mylk4*,*Mylk2*,*Mylpf*,*Actn2*,*Mapk10*,*Col4a6*,*Spp1*
  Cardiac muscle contraction                0.00210     *Tnnt2*,*Actc1*,*Cox6a2*,*Myh7*,*Myh6*,*Tnni3*
  cAMP signalling pathway                   0.00858     *Fos*,*Htr1b*,*Adcy7*,*Chrm2*,*Gria1*,*Pln*,*Mapk10*,*Tnni3*
  Gastric acid secretion                    0.01023     *Kcnj15*,*Adcy7*,*Mylk3*,*Mylk4*,*Mylk2*
  cGMP‐PKG signalling pathway               0.01252     *Irs2*,*Irs3*,*Adcy7*,*Pln*,*Mylk3*,*Mylk4*,*Mylk2*
  Regulation of actin cytoskeleton          0.01284     *Myl7*,*Chrm2*,*Mylk3*,*Mylk4*,*Mylk2*,*Mylpf*,*Actn2*,*Fgf12*
  Hypertrophic cardiomyopathy (HCM)         0.01404     *Tnnt2*,*Actc1*,*Mybpc3*,*Ttn*,*Tnni3*
  Calcium signalling pathway                0.01955     *Adcy7*,*Tnnc2*,*Chrm2*,*Pln*,*Mylk3*,*Mylk4*,*Mylk2*
  Chemokine signalling pathway              0.02828     *Adcy7*,*Ccr5*,*Ccr2*,*Ccl9*,*Ccl8*,*Ccl7*,*Ccl6*
  Circadian entrainment                     0.02853     *Kcnj5*,*Fos*,*Adcy7*,*Gria1*,*Per1*
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In conclusion, our analysis expands the understanding of the pathobiology of Marfan disease progression. Our analysis revealed several genes previously unknown to be involved in aorta‐specific Marfan disease that may be important targets for designing more appropriate therapeutic strategies for the treatment of MFS.
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